Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arcturus Therapeutics In...

    NASDAQ: ARCT · Real-Time Price · USD
    13.29
    -1.12 (-7.77%)
    At close: Jun 27, 2025, 3:59 PM
    13.92
    4.70%
    After-hours: Jun 27, 2025, 05:05 PM EDT
    -7.77%
    Bid 13.1
    Market Cap 360.57M
    Revenue (ttm) 135.17M
    Net Income (ttm) -68.2M
    EPS (ttm) -2.52
    PE Ratio (ttm) -5.28
    Forward PE -5.05
    Analyst Buy
    Ask 14.9
    Volume 473,403
    Avg. Volume (20D) 454,987
    Open 14.32
    Previous Close 14.41
    Day's Range 13.28 - 14.53
    52-Week Range 8.04 - 25.88
    Beta 2.29

    About ARCT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ARCT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ARCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Arcturus Therapeutics Inc. is scheduled to release its earnings on Aug 4, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 weeks ago
    +7.7%
    Arcturus Therapeutics shares are trading higher af... Unlock content with Pro Subscription
    1 month ago
    +2.33%
    Arcturus Therapeutics shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.
    news image

    4 days ago · businesswire.com

    Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

    SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Arcturus--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development o...

    news image

    3 weeks ago · zacks.com

    Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet

    The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

    news image

    1 month ago · businesswire.com

    Arcturus Therapeutics to Attend Upcoming Investor Conferences

    SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the developme...

    news image

    1 month ago · zacks.com

    Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade

    The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

    news image

    1 month ago · seekingalpha.com

    Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

    Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Re...

    news image

    1 month ago · zacks.com

    Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

    Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago.

    news image

    1 month ago · zacks.com

    Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline

    Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · businesswire.com

    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

    SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...

    news image

    2 months ago · zacks.com

    Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

    The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

    Add to Watchlist